Biohaven Ltd BHVN

NYS: BHVN | ISIN: VGG111961055   30/04/2025
22,12 USD (+1,10%)
(+1,10%)   30/04/2025

28 april 2025 · Biohaven Announces Investment up to $600 Million by Oberland Capital · Persbericht

5 april 2025 · Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting · Persbericht

3 maart 2025 · Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 · Persbericht

3 maart 2025 · Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results · Persbericht

8 augustus 2024 · Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments · Persbericht

29 mei 2024 · Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day · Persbericht

29 mei 2024 · Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors · Persbericht

9 mei 2024 · Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments · Persbericht

22 april 2024 · Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares · Persbericht

18 april 2024 · Biohaven Announces Pricing of $230 Million Public Offering of Common Shares · Persbericht

17 april 2024 · Biohaven Announces Proposed Public Offering of Common Shares · Persbericht

13 april 2024 · Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates · Persbericht

29 februari 2024 · Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments · Persbericht

8 januari 2024 · Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology · Persbericht

2 januari 2024 · Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

1 december 2023 · Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting · Persbericht

16 oktober 2023 · Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® · Persbericht

5 oktober 2023 · Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares · Persbericht

3 oktober 2023 · Biohaven Announces Pricing of $225 Million Public Offering of Common Shares · Persbericht

2 oktober 2023 · Biohaven Announces Proposed Public Offering Of Common Shares · Persbericht

Mijn selecties